Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.
Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Dianosic SAS is a healthcare organization based in Strasbourg, France, founded in 2017. The company specializes in developing innovative medical devices for Ear, Nose, and Throat (ENT) conditions. Its flagship product, the CAVI-T, is an asymmetrical intranasal balloon designed to manage spontaneous or postoperative bleeding through low-pressure compression, tailored to the unique anatomy of the nasal cavity. This device also features an active balloon that minimizes biofilm formation, targets specific bacteria, and promotes healing. Additionally, Dianosic is developing an Active Resorbable Intranasal Scaffold device aimed at treating chronic sinusitis in patients who do not respond to conventional drug therapies. These advancements enable healthcare professionals to monitor patients remotely, enhancing post-operative care and overall treatment efficacy.
Guerbet is a healthcare company specializing in medical imaging, with a focus on manufacturing and marketing contrast agents for diagnostic purposes. With nearly 90 years of experience, it is the only pharmaceutical group dedicated solely to medical imaging globally, operating in almost 80 countries through subsidiaries and distributors. Guerbet's product portfolio includes a comprehensive range of contrast agents for various imaging modalities, such as X-ray, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and nuclear medicine. The company also offers injectors and related medical devices designed to enhance patient diagnosis and prognosis. Its well-known brands include Xenetix, Optiray, Dotarem, and others, all aimed at improving the quality of life for patients.
Operator of a biotechnology company intended to develop drugs targeting specifically a new class of proteins involved in the resolution of inflammation. The company develops treatments based on monoclonal antibodies by treating human mucosal inflammatory diseases by inhibiting a target that could be implied in the early inflammatory process and the recruitment of innate immunity cells, enabling healthcare providers to cure their patients.
Ludocare focuses on developing therapeutic robots that assist patients with chronic diseases and their families. The company's innovative devices are designed to complement traditional drug treatments by providing personalized support that enhances treatment efficiency. By empowering patients, especially children, Ludocare aims to improve therapeutic compliance both quantitatively and qualitatively. This approach facilitates better disease management and helps stabilize essential treatments, ultimately contributing to improved autonomy and quality of life for patients and their families.
Developer of an artificial intelligence-based fetal ultrasound software intended to analyze and diagnose congenital malformations. The company's software combines the patient's medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis and assists sonographers during prenatal screening scans, enabling healthcare practitioners to receive crucial support in conducting fetal ultrasound and mothers to take care of themselves and their children.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.
Diabeloop SAS is a medical device company based in Grenoble, France, that specializes in developing an electronic artificial pancreas for individuals with Type 1 diabetes. Founded in 2015, the company's innovative system comprises a continuous glucose sensor that monitors blood sugar levels and a smartphone application that communicates with a connected insulin pump to administer the optimal insulin dosage automatically. This closed-loop system aims to minimize the risk of hypoglycemia and related complications, thereby improving the quality of life for patients. By integrating advanced technology and artificial intelligence, Diabeloop seeks to streamline diabetes management, reducing the mental burden on users and allowing them to lead more uninterrupted lives.
Implicity is a developer of a remote monitoring platform that enables the smart monitoring of patients with connected pacemakers and defibrillators. The platform utilizes artificial intelligence to sort and summarize patient data, assessing the criticality of alerts based on each patient's medical context. This innovative approach allows cardiologists and healthcare professionals to automate the remote monitoring process, consolidating patients' telepulse information into a single platform. By enhancing the efficiency of monitoring, Implicity aims to support hospital teams in delivering optimal quality care to their patients.
Guard Medical is the developer of NPseal™. We are an innovation driven company focused on creating easy-to-use and cost-effective solutions that enable prophylactic NPWT wound care of closed surgical incisions.
LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.
Invivox is an innovative online platform that connects medical professionals for practical, in situ training sessions, primarily in small groups or one-on-one settings. By facilitating these interactions among doctors worldwide, Invivox aims to enhance medical education and ultimately improve patient care. The platform not only offers interactive online classes but also publishes weekly medical magazines and curates specialized training opportunities in collaboration with a network of international experts. Through these initiatives, Invivox democratizes access to knowledge in the healthcare sector, providing valuable mentorship across various medical specialties.
Archeon is focused on creating innovative solutions for the monitoring, diagnosis, and treatment of critically ill patients in prehospital care. The company develops artificial intelligence-based technologies aimed at enhancing ventilation quality in emergency medical services. Its products are designed to be practical, user-friendly, and intuitive for emergency caregivers, providing real-time feedback on the quality of ventilation administered to patients. This approach aims to improve patient outcomes and support medical professionals in high-pressure situations.
Doctolib is an online booking platform and management software provider based in Paris, France, that serves the healthcare sector across Europe. Established in 2013, the platform connects patients with healthcare practitioners, facilitating the scheduling of appointments with ease. With 25 million monthly visitors, it supports 65,000 health practitioners in over 1,300 facilities, offering a comprehensive service that enhances appointment management, reduces no-show rates, and attracts new patients. For patients, Doctolib provides a free service that allows them to find nearby doctors or dentists and book appointments 24/7 in just a few clicks. The platform aims to streamline access to healthcare services for both practitioners and patients, improving overall efficiency in the healthcare system.
Susu is a health tech company focused on providing accessible and affordable healthcare services to families in the African diaspora. The company offers a comprehensive range of services, including preventive care, medical treatments, chronic disease management, and authentic medications. By delivering health bundle services through its platform, Susu aims to facilitate long-term health support for patients, ensuring effective monitoring of various health conditions such as pregnancy and chronic diseases. This approach enables individuals to access quality healthcare services and insurance, promoting overall well-being within the communities it serves.
Susu is a health tech company focused on providing accessible and affordable healthcare services to families in the African diaspora. The company offers a comprehensive range of services, including preventive care, medical treatments, chronic disease management, and authentic medications. By delivering health bundle services through its platform, Susu aims to facilitate long-term health support for patients, ensuring effective monitoring of various health conditions such as pregnancy and chronic diseases. This approach enables individuals to access quality healthcare services and insurance, promoting overall well-being within the communities it serves.
Cureety SAS is a healthcare technology company based in Dinan, France, established in 2018. The company has developed an interoperable telemedicine platform designed to enhance the care and follow-up of cancer patients. Its application integrates seamlessly into healthcare settings, providing tools that assist professionals in managing cancer treatments. Additionally, Cureety collects real-world data, which supports researchers and industrialists in improving patient care and advancing research initiatives related to anti-tumor therapies. Through its innovative approach, Cureety aims to transform the care pathway for individuals affected by cancer.
Spartha Medical is a medical technology company focused on developing eco-friendly, invisible coatings designed for medical devices and consumer products to mitigate microbial and inflammatory risks. Utilizing natural biopolymers, the company’s innovative coatings possess antibacterial, antiviral, and anti-inflammatory properties, providing an effective solution for infection control. The technology relies on a patented method of supramolecular assembly, enabling precise control over the properties of the coatings based on specific applications. This approach allows for the creation of multifunctional and easy-to-apply surface treatments that help healthcare institutions maintain disease-free environments on medical devices.
HypnoVR SAS specializes in virtual reality-based medical hypnosis solutions aimed at managing pain and stress in patients. Founded in 2016 and based in Strasbourg, France, the company has developed a unique application that integrates virtual reality technology with medical hypnosis, effectively used in various medical fields, including pediatric surgery, gastroenterology, gynecology, and dental surgery. HypnoVR also focuses on research initiatives that explore the use of medical hypnosis in anesthesia to alleviate patients' stress and anxiety during medical procedures. In addition to its software solutions, the company offers specialized hardware designed for medical applications, catering to health professionals and institutions seeking innovative approaches to enhance patient care.
MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.
Quantum Surgical is a provider of surgical robotics focused on developing innovative solutions for minimally invasive surgeries. The company is creating a novel robotic platform designed to enhance the assessment, planning, and treatment of medical conditions. Its technology supports advanced percutaneous ablation therapy, particularly for liver cancer treatment, aiming to improve patient outcomes and enhance the safety of interventional oncology procedures. With a commitment to delivering effective clinical solutions, Quantum Surgical seeks to represent unique spinal products and treatment options, benefiting both physicians and patients throughout the continuum of care.
Echoliv is a medical technology company specializing in artificial intelligence solutions for abdominal ultrasound. The company develops software designed to assist radiologists and hepatologists in early-stage screening for hepatocellular carcinoma, the most common type of liver cancer. Echoliv's flagship product, Ultraliv, employs advanced algorithms to identify nodules that may be overlooked by practitioners, enhancing diagnostic accuracy and improving patient care. By integrating AI into the ultrasound process, Echoliv aims to support healthcare professionals in delivering timely and effective treatment for liver cancer.
Developer of a tele-expertise platform designed to facilitate phone-based medical verification for patients eligible for health insurance facilities. The company's platform allows medical institutions or private physicians to secure and value informal opinions, strengthen the links between first and second recourse, centralize and promote requests from correspondents, and discover and contact doctors and organizations, enabling clients to improve, secure, and enhance the opinions exchanged and automate administrative tasks.
UroMems SAS is a French company founded in 2011 and headquartered in Grenoble, specializing in the design, development, and commercialization of implantable medical devices. The company has created the MyoElectroMechanical System, an electronic artificial urinary sphincter (eAUS) aimed at patients suffering from severe urinary incontinence. This device functions by increasing urethral pressure during physically demanding activities and decreasing it when less compression is needed. UroMems emphasizes addressing specific clinical needs that significantly impact patients' quality of life, with a focus on improving surgical treatments and reducing associated side effects.
OncoDiag is a French biotechnology company located in Normandy, dedicated to creating non-invasive diagnostic tests aimed at the early detection of cancers. Its flagship product, the Urotest, is a urine test approved for the diagnosis and monitoring of bladder cancer. In addition to the Urotest, OncoDiag is developing Colodiag, a test focused on the early identification of colorectal cancer, and other diagnostic tools, including a tissue-based test for predicting non-evolutive localized prostate cancer. Through its innovative testing kits, OncoDiag aims to enhance cancer diagnostics, allowing healthcare professionals to provide timely and effective patient care.
Omini is a company that specializes in the development of portable and multipurpose bio-sensing devices for blood tests, catering primarily to general practitioners. Established in 2019 and headquartered in Saint Mandé, France, Omini addresses a critical need in medical decision-making, as 70% of such decisions rely on clinical chemistry and assays like blood tests, which often require hours to days to yield results. The company’s innovative devices utilize multiplex electrochemical biosensor technology to simultaneously identify, analyze, and monitor multiple target biomarkers in real-time, allowing for quicker and more informed medical decisions. This technology not only facilitates decentralized testing and at-home monitoring for patients with chronic conditions but also aims to alleviate pressure on healthcare systems by providing affordable and immediate testing solutions.
Provider of consulting services focused on information systems security, digital strategy and project management for health organizations. The company offers to build patient and user experience, taking advantage of digital innovation, support and facilitating professional practice catering to the health sector to reconcile economic, ethical and societal challenges.
Grapheal introduces digital biosensing technology into embedded systems for on-site diagnostics and remote patient monitoring. Current applications are wound care digital assistant for improving the follow-up of difficult to heal wounds.
Surgivisio SAS is a French company, established in 2009 and based in La Tronche, that specializes in developing and manufacturing healthcare technologies. The company's focus lies in 2D and 3D imaging, real-time surgical navigation, and computer-assisted minimally-invasive surgery, with a particular emphasis on applications in orthopedics and traumatology. The Surgivisio device is classified as a CE-marked IIb-class medical device, indicating its compliance with regulatory standards for safety and effectiveness. Conformity assessment for the device has been conducted by G-MED, ensuring adherence to industry regulations.
OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.
Lucine is focused on transforming patient health, primarily in the area of pain management. The company has developed a mobile health application that measures, analyzes, and alleviates pain from the comfort of home. Utilizing advanced algorithms, the application identifies the nature of a patient's pain by analyzing facial expressions, vocal cues, and posture. Based on this real-time assessment, it personalizes treatment options, offering techniques such as exercises, relaxation methods, art therapy, and meditation. The application aims to provide relief within five minutes through innovative analgesic neurostimulation, empowering patients with chronic pain to manage their symptoms effectively.
Medaviz is a online platform which provides medical advice to bring patients and doctors into immediate contact.
Multiwave Imaging is a French company recognized as a leader in the design of metamaterial MRI antennas. It operates as a wholly owned subsidiary of Multiwave Technologies AG, which was founded in Switzerland in March 2015 and has its headquarters in Geneva. The company focuses on developing innovative metamaterial technologies aimed at enhancing quality of life. Multiwave Imaging's primary objective is to create and harness intellectual property, assess its commercial viability, and establish management teams to transform these innovations into marketable products. This strategic approach enables Multiwave Imaging to build companies across various sectors, leveraging advanced technology to address diverse needs.
Synapse Medicine is a company based in Bordeaux, France, founded in 2017, that develops an online platform aimed at assisting healthcare professionals, including doctors and pharmacists. The platform provides reliable and up-to-date information about medications, allowing users to analyze prescriptions in real-time and enhance the safety of drug therapies. By offering access to critical medical intelligence, Synapse Medicine enables healthcare providers to make informed decisions and ensure better outcomes for patients through virtual medical assistance.
MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.
Quantum Surgical is a provider of surgical robotics focused on developing innovative solutions for minimally invasive surgeries. The company is creating a novel robotic platform designed to enhance the assessment, planning, and treatment of medical conditions. Its technology supports advanced percutaneous ablation therapy, particularly for liver cancer treatment, aiming to improve patient outcomes and enhance the safety of interventional oncology procedures. With a commitment to delivering effective clinical solutions, Quantum Surgical seeks to represent unique spinal products and treatment options, benefiting both physicians and patients throughout the continuum of care.
Ambler SAS, founded in 2018 and headquartered in Paris, France, offers a digital platform that facilitates the booking of private ambulances, medical transportation services, and approved taxis for individuals and healthcare institutions. The company aims to streamline the process of medical transport by connecting healthcare prescribers with ambulance operators through an efficient online system that is secure and free for users. Ambler aggregates a substantial fleet of vehicles through strategic partnerships, ensuring high availability and responsiveness to the growing demand for medical transportation driven by demographic changes and regulatory reforms in the healthcare sector. Supported by both public authorities and notable private investors, Ambler is positioned as a unique solution in the marketplace for medical transport services.
UroMems SAS is a French company founded in 2011 and headquartered in Grenoble, specializing in the design, development, and commercialization of implantable medical devices. The company has created the MyoElectroMechanical System, an electronic artificial urinary sphincter (eAUS) aimed at patients suffering from severe urinary incontinence. This device functions by increasing urethral pressure during physically demanding activities and decreasing it when less compression is needed. UroMems emphasizes addressing specific clinical needs that significantly impact patients' quality of life, with a focus on improving surgical treatments and reducing associated side effects.
UroMems SAS is a French company founded in 2011 and headquartered in Grenoble, specializing in the design, development, and commercialization of implantable medical devices. The company has created the MyoElectroMechanical System, an electronic artificial urinary sphincter (eAUS) aimed at patients suffering from severe urinary incontinence. This device functions by increasing urethral pressure during physically demanding activities and decreasing it when less compression is needed. UroMems emphasizes addressing specific clinical needs that significantly impact patients' quality of life, with a focus on improving surgical treatments and reducing associated side effects.
Dianosic SAS is a healthcare organization based in Strasbourg, France, founded in 2017. The company specializes in developing innovative medical devices for Ear, Nose, and Throat (ENT) conditions. Its flagship product, the CAVI-T, is an asymmetrical intranasal balloon designed to manage spontaneous or postoperative bleeding through low-pressure compression, tailored to the unique anatomy of the nasal cavity. This device also features an active balloon that minimizes biofilm formation, targets specific bacteria, and promotes healing. Additionally, Dianosic is developing an Active Resorbable Intranasal Scaffold device aimed at treating chronic sinusitis in patients who do not respond to conventional drug therapies. These advancements enable healthcare professionals to monitor patients remotely, enhancing post-operative care and overall treatment efficacy.
Cureety SAS is a healthcare technology company based in Dinan, France, established in 2018. The company has developed an interoperable telemedicine platform designed to enhance the care and follow-up of cancer patients. Its application integrates seamlessly into healthcare settings, providing tools that assist professionals in managing cancer treatments. Additionally, Cureety collects real-world data, which supports researchers and industrialists in improving patient care and advancing research initiatives related to anti-tumor therapies. Through its innovative approach, Cureety aims to transform the care pathway for individuals affected by cancer.
Multiwave Imaging is a French company recognized as a leader in the design of metamaterial MRI antennas. It operates as a wholly owned subsidiary of Multiwave Technologies AG, which was founded in Switzerland in March 2015 and has its headquarters in Geneva. The company focuses on developing innovative metamaterial technologies aimed at enhancing quality of life. Multiwave Imaging's primary objective is to create and harness intellectual property, assess its commercial viability, and establish management teams to transform these innovations into marketable products. This strategic approach enables Multiwave Imaging to build companies across various sectors, leveraging advanced technology to address diverse needs.
Cardiologs Technologies SAS is a medical technology company based in Paris, France, founded in 2014. It specializes in the development of a cloud-based platform for electrocardiogram (ECG) analysis that enhances the management of cardiac patients. The Cardiologs ECG Analysis Platform leverages medical-grade artificial intelligence and deep learning technology to assist physicians in screening for conditions such as atrial fibrillation and other arrhythmias. The platform analyzes long-term ambulatory ECG recordings and recognizes patterns in digital ECG signals, providing clinicians with critical insights for interpreting heart disorders. Cardiologs aims to democratize expert cardiac care by making advanced diagnostics accessible to healthcare practitioners globally. Its extensive database of over 1,450,000 recordings, supported by clinical publications, underpins its commitment to delivering high-quality cardiac diagnostics.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
Deeplink-Medical is the answer to the real needs of the field apprehended by the founding medical team and the inadequacy of available telemedicine IT solutions. The design of innovative tools led by an experienced medical team, coupled with a framework of practices (support, training, medical protocol, activity monitoring) ensure the success of a telemedicine project and the optimization of the management patients.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic
Volta Medical is a start-up based in Marseille, France, that specializes in developing artificial intelligence software for interventional cardiology, particularly focusing on the treatment of atrial fibrillation, the most common cardiac arrhythmia. Founded in 2016, the company has created AIFib, its first AI software that enhances the functionality of mapping catheters used in the analysis of electrograms and the treatment of arrhythmias. Volta Medical aims to provide innovative solutions that assist cardiologists during interventional procedures, embodying expertise in both interventional cardiology and intracardiac signal analysis. The company's commitment to advancing its technology and products is reflected in its efforts to recruit top talent and its recognition from the European Commission, which awarded its technology a "Seal of Excellence."
Neurallys is a Paris-based company focused on the development and production of medical devices specifically for neurology and neurosurgery. The company is creating an intelligent sensor that communicates with a smartphone to monitor intracranial pressure in patients suffering from hydrocephalus. This innovative device aims to enhance the efficiency of neurosurgeons in monitoring the condition, ultimately improving patient care and outcomes.
Doctolib is an online booking platform and management software provider based in Paris, France, that serves the healthcare sector across Europe. Established in 2013, the platform connects patients with healthcare practitioners, facilitating the scheduling of appointments with ease. With 25 million monthly visitors, it supports 65,000 health practitioners in over 1,300 facilities, offering a comprehensive service that enhances appointment management, reduces no-show rates, and attracts new patients. For patients, Doctolib provides a free service that allows them to find nearby doctors or dentists and book appointments 24/7 in just a few clicks. The platform aims to streamline access to healthcare services for both practitioners and patients, improving overall efficiency in the healthcare system.
SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.
Happytal, SAS offers concierge services to hospitals in France. Its services include providing a hairdresser in the room, a beautician, to receive the newspaper, and to offer a basket of fruits and meals. The company was founded in 2013 and is based in Vanves, France.
Lattice Medical is a medical technology company based in Loos, France, founded in 2017. The company specializes in the design and manufacture of innovative prostheses for women who have undergone mastectomy due to breast cancer. Its flagship product, MATTISSE, addresses significant clinical and societal needs by enabling natural breast reconstruction. MATTISSE uses a combination of biomaterials and tissue engineering, including 3D printing, to create custom implants that regenerate autologous adipose tissue. This technology allows for a single surgical procedure, as the fully biodegradable implants dissolve after reconstruction, minimizing invasiveness and pain while reducing surgery time. Lattice Medical aims to replace traditional silicone-based implants with its advanced solutions, thereby enhancing the quality of life for women affected by breast cancer.
C4Diagnostics is a company based in Marseille, France, that specializes in the development and commercialization of in vitro diagnostic (IVD) kits. Founded in 2017, the company focuses on creating technology that enables the detection, counting, and concentration of culturable microorganisms in clinical microbiology. Its innovative approach is designed to enhance the speed and sensitivity of diagnostic tests, particularly for urinary tract infections. By providing hospitals and laboratories with advanced tools for culture-based testing and specific fluorescence, C4Diagnostics aims to improve diagnostic accuracy and efficiency in medical settings.
Doctoconsult SAS is a French company that specializes in providing online healthcare consultation services, focusing primarily on mental health. Founded in 2016 and headquartered in Fresnes, France, it offers support for a range of issues including depressive states, sleep disorders, anxiety, phobias, eating disorders, addictions, and family problems. Notably, it is recognized as the first video consultation service dedicated to psychiatrists in France. The company has recently launched an innovative app developed in collaboration with key opinion leaders and researchers aimed at assisting patients with mental disorders.
Invivox is an innovative online platform that connects medical professionals for practical, in situ training sessions, primarily in small groups or one-on-one settings. By facilitating these interactions among doctors worldwide, Invivox aims to enhance medical education and ultimately improve patient care. The platform not only offers interactive online classes but also publishes weekly medical magazines and curates specialized training opportunities in collaboration with a network of international experts. Through these initiatives, Invivox democratizes access to knowledge in the healthcare sector, providing valuable mentorship across various medical specialties.
LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.
Surgivisio SAS is a French company, established in 2009 and based in La Tronche, that specializes in developing and manufacturing healthcare technologies. The company's focus lies in 2D and 3D imaging, real-time surgical navigation, and computer-assisted minimally-invasive surgery, with a particular emphasis on applications in orthopedics and traumatology. The Surgivisio device is classified as a CE-marked IIb-class medical device, indicating its compliance with regulatory standards for safety and effectiveness. Conformity assessment for the device has been conducted by G-MED, ensuring adherence to industry regulations.
Emy is a medical device developed by Fizimed SAS, designed to assist women in managing urinary incontinence through pelvic floor rehabilitation. This innovative perineal probe connects to a mobile application, allowing users to engage in customized exercises that strengthen pelvic floor muscles. The device captures real-time muscle contractions, enabling users to complete five-minute workouts through interactive games, which helps maintain motivation. By simplifying the interface for home use, Emy aims to make pelvic floor training accessible and engaging. The company emphasizes the importance of addressing the stigma surrounding urinary incontinence, which affects a significant number of women. Fizimed is committed to creating a supportive community for women to openly discuss their challenges and share solutions, while also providing a quality medical device that combines safety with an enjoyable user experience.
TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.
Doctolib is an online booking platform and management software provider based in Paris, France, that serves the healthcare sector across Europe. Established in 2013, the platform connects patients with healthcare practitioners, facilitating the scheduling of appointments with ease. With 25 million monthly visitors, it supports 65,000 health practitioners in over 1,300 facilities, offering a comprehensive service that enhances appointment management, reduces no-show rates, and attracts new patients. For patients, Doctolib provides a free service that allows them to find nearby doctors or dentists and book appointments 24/7 in just a few clicks. The platform aims to streamline access to healthcare services for both practitioners and patients, improving overall efficiency in the healthcare system.
Private Equity Round in 2017
Belovia has designs, manufactures and markets medical devices and equipment (electronic stocking donners, light solutions for physical mobilization, etc.).
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
Cardiologs Technologies SAS is a medical technology company based in Paris, France, founded in 2014. It specializes in the development of a cloud-based platform for electrocardiogram (ECG) analysis that enhances the management of cardiac patients. The Cardiologs ECG Analysis Platform leverages medical-grade artificial intelligence and deep learning technology to assist physicians in screening for conditions such as atrial fibrillation and other arrhythmias. The platform analyzes long-term ambulatory ECG recordings and recognizes patterns in digital ECG signals, providing clinicians with critical insights for interpreting heart disorders. Cardiologs aims to democratize expert cardiac care by making advanced diagnostics accessible to healthcare practitioners globally. Its extensive database of over 1,450,000 recordings, supported by clinical publications, underpins its commitment to delivering high-quality cardiac diagnostics.
BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic
OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.
TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.
Doctolib is an online booking platform and management software provider based in Paris, France, that serves the healthcare sector across Europe. Established in 2013, the platform connects patients with healthcare practitioners, facilitating the scheduling of appointments with ease. With 25 million monthly visitors, it supports 65,000 health practitioners in over 1,300 facilities, offering a comprehensive service that enhances appointment management, reduces no-show rates, and attracts new patients. For patients, Doctolib provides a free service that allows them to find nearby doctors or dentists and book appointments 24/7 in just a few clicks. The platform aims to streamline access to healthcare services for both practitioners and patients, improving overall efficiency in the healthcare system.
Nomadeec is a mobile telemedicine platform developed by Exelus SAS, specializing in emergency and programmed care. As a leader in remote medical control in France, it offers a powerful tool for enhancing decision-making in urgent medical situations, ultimately improving patient outcomes. The platform is designed to accommodate various healthcare professionals, including emergency doctors, sports doctors, and paramedics, enabling them to conduct teleconsultations, tele-expertise, and tele-triage. By optimizing prehospital care and bridging gaps in healthcare accessibility, Nomadeec facilitates both scheduled and unscheduled medical consultations, thereby reducing the need for unnecessary hospitalizations and improving the efficiency of emergency responses.
UroMems SAS is a French company founded in 2011 and headquartered in Grenoble, specializing in the design, development, and commercialization of implantable medical devices. The company has created the MyoElectroMechanical System, an electronic artificial urinary sphincter (eAUS) aimed at patients suffering from severe urinary incontinence. This device functions by increasing urethral pressure during physically demanding activities and decreasing it when less compression is needed. UroMems emphasizes addressing specific clinical needs that significantly impact patients' quality of life, with a focus on improving surgical treatments and reducing associated side effects.
H4D is a French company founded in 2008 that specializes in designing and developing telehealth booths, particularly through its product, the Consult Station. This device enables remote medical consultations by allowing users to conduct self-check-ups and facilitating the monitoring of both acute and chronic diseases. H4D aims to enhance access to healthcare, addressing geographic and social isolation while promoting preventative medicine. The company serves diverse clients, including local authorities, senior care facilities, hospitals, corporations, and insurance providers, ensuring that its health solutions are integrated into broader healthcare strategies. H4D is committed to maintaining effective communication with local healthcare stakeholders to support its health programs and enhance overall accessibility to medical care.
Private Equity Round in 2016
MédiPôle Partenaires is a group of private clinics whose competence is particularly recognized in the fields of Medicine of Obstetric Surgery (MCO), Continuing Care and Rehabilitation (SSR) and Home Hospitalization (HAD).
MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.
Cardiologs Technologies SAS is a medical technology company based in Paris, France, founded in 2014. It specializes in the development of a cloud-based platform for electrocardiogram (ECG) analysis that enhances the management of cardiac patients. The Cardiologs ECG Analysis Platform leverages medical-grade artificial intelligence and deep learning technology to assist physicians in screening for conditions such as atrial fibrillation and other arrhythmias. The platform analyzes long-term ambulatory ECG recordings and recognizes patterns in digital ECG signals, providing clinicians with critical insights for interpreting heart disorders. Cardiologs aims to democratize expert cardiac care by making advanced diagnostics accessible to healthcare practitioners globally. Its extensive database of over 1,450,000 recordings, supported by clinical publications, underpins its commitment to delivering high-quality cardiac diagnostics.
Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.
Magnisense conçoit, développe et commercialise des tests de diagnostic d'urgence pour les maladies cardio-vasculaires à partir de sa technologie MIAtek® et de son instrument de diagnostic propriétaires
Voluntis, Inc. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. It offers Insulia, a prescription-only medical device that provides type 2 diabetes patients with insulin dose recommendations and educational coaching messages based on blood glucose values and other diabetes-related data; and Diabeo, a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen, which suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. Voluntis, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Skuldtech is specialized in the discovery of new Biomarkers and the development of Diagnostics focused on personalized medicine applications. This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics associated with new treatments, especially in cancer, neurodegenerative and infectious diseases.